NMNH: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder. 2. Bontac is a very first manufacture in the world to produce the NMNH powder on the level of high purity, stability. 3. Exclusive “Bonpure” seven-step purification technology, high purity(up to 99%) and stability of production of NMNH powder 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMNH powder 5. Provide one-stop product solution customization service
NADH: 1. Bonzyme whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive Bonpure seven-step purification technology, purity up higher than 98 % 3. Special patented process crystal form, higher stability 4. Obtained a number of international certifications to ensure high quality 5. 8 domestic and foreign NADH patents, leading the industry 6. Provide one-stop product solution customization service
NAD: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Stable supplier of 1000+ enterprises around the world 3. Unique “Bonpure” seven-step purification technology, higher product content and higher conversion rate 4. Freeze drying technology to ensure stable product quality 5. Unique crystal technology, higher product solubility 6. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products
NMN: 1. “Bonzyme”Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive“Bonpure”seven-step purification technology, high purity(up to 99.9%) and stability 3. Industrial leading technology: 15 domestic and international NMN patents 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products 5. Multiple in vivo studies show that Bontac NMN is safe and effective 6. Provide one-stop product solution customization service 7. NMN raw material supplier of famous David Sinclair team of Harvard University
Bontac Bio-Engineering (Shenzhen) Co., Ltd. (hereafter referred to as BONTAC) is a high-tech enterprise established in July 2012. BONTAC integrates R&D, production and sales, with enzyme catalysis technology as the core and coenzyme and natural products as main products. There are six major series of products in BONTAC, involving coenzymes, natural products, sugar substitutes, cosmetics, dietary supplements and medical intermediates.
As the leader of the global NMN industry, BONTAC has the first whole-enzyme catalysis technology in China. Our coenzyme products are widely used in health industry, medical & beauty, green agriculture, biomedicine and other fields. BONTAC adheres to independent innovation, with more than 170 invention patents. Different from the traditional chemical synthesis and fermentation industry, BONTAC has advantages of green low-carbon and high-value-added biosynthesis technology. What’s more, BONTAC has established the first coenzyme engineering technology research center at the provincial level in China which also is the sole in Guangdong Province.
In the future, BONTAC will focus on its advantages of green, low-carbon and high-value-added biosynthesis technology, and build ecological relationship with academia as well as upstream/downstream partners, continuously leading the synthetic biological industry and creating a better life for human beings.
NMN (Nicotinamide Mononucleotide) is a substance similar to vitamin B3, which can produce NAD+ (a key metabolic intermediate) in the body. Therefore, studies have shown that NMN may help improve aging-related health issues such as metabolism, immunity, cell repair, brain health, and more.
Currently, NMN supplements are mainly used to treat the following diseases:
Aging-related metabolic disorders such as diabetes, obesity, high cholesterol, etc.
Aging-related neurodegenerative diseases, such as Alzheimer's disease.
Aging-associated immune decline.
Aging-related cardiovascular disease.
NMN supplements are mainly used to increase NAD+ levels to improve metabolic diseases and slow down the aging process.
Improve metabolic diseases: Studies have shown that NMN can improve the symptoms of metabolic diseases such as diabetes, fatty liver and obesity.
Delay the aging process: NMN can increase the vitality of cells, improve the metabolic process of cells, and delay the aging process.
Protect DNA: NAD+ is an important metabolic substance in cells and participates in various biological processes such as cellular energy metabolism and DNA repair. Supplementing NMN can increase NAD+ levels and protect DNA.
Improves Athletic Capacity: NMN has been shown to improve athletic performance and increase fat burning ability
Improve neurodegenerative diseases: Studies have shown that NMN can improve neurodegenerative diseases, such as Alzheimer's disease
However, these studies were small, and NMN has not been shown to be effective in clinical trials, so further research is needed to determine the effectiveness of NMN supplements.
NMN supplements are mainly used to increase NAD+ levels to improve metabolic diseases and slow down the aging process.
Improve metabolic diseases: Studies have shown that NMN can improve the symptoms of metabolic diseases such as diabetes, fatty liver and obesity.
Delay the aging process: NMN can increase the vitality of cells, improve the metabolic process of cells, and delay the aging process.
Protect DNA: NAD+ is an important metabolic substance in cells and participates in various biological processes such as cellular energy metabolism and DNA repair. Supplementing NMN can increase NAD+ levels and protect DNA.
Improves Athletic Capacity: NMN has been shown to improve athletic performance and increase fat burning ability
Improve neurodegenerative diseases: Studies have shown that NMN can improve neurodegenerative diseases, such as Alzheimer's disease
NMN supplements may cause side effects such as upset stomach, diarrhea, and nausea. There is also research showing that NMN supplements may affect insulin sensitivity and insulin levels, so people with diabetes should consult their doctor before taking them.
NMN supplements have not yet undergone large-scale clinical trials to verify their effectiveness. Currently, research on NMN supplements is mainly focused on animal and in vitro experiments. These studies show that NMN can improve the symptoms of metabolic diseases such as diabetes, fatty liver and obesity, and can delay the aging process.
The long-term health effects of NMN supplementation are not well studied. Existing studies mainly focus on animal and in vitro experiments, which show that NMN can improve the symptoms of metabolic diseases such as diabetes, fatty liver and obesity, and can delay the aging process. However, the results of these studies do not represent the long-term effects of NMN on human health.
1. Introduction Mitochondria are the center of energy metabolism in cardiomyocytes, which are necessary for maintaining normal myocardial contractility and cardiac function. Typically, the development of cardiovascular disease is usually accompanied by mitochondrial dysfunction. Impaired autophagy is known to cause mitochondrial dysfunction and heart failure, in part due to altered mitophagy and protein quality control. Notably, external replenishment of nicotinamide adenine dinucleotide (NAD+) precursors can enhance autophagy and mitochondrial quality control to maintain metabolic health, thereby regulate mitochondrial and cardiac function. 2. NAD+ metabolism in mitochondrial and cardiac function Cardiomyocytes accumulate NAD+ mostly within their mitochondria, where the bulk of cellular oxidation-reduction reactions occur. However, NAD+ is also present in the cytosol and nucleus, in which NAD+-derived metabolites and NAD+-dependent enzymes contribute to various cellular functions. 3. Mitochondrial and cardiac dysfunction induced by NAD+ deficiency Mitochondrial and cardiac dysfunction triggered by NAD+ deficiency is alleviated in cAtg3-KO mouse hearts post the administration of β-nicotinamide mononucleotide (NMN), as evidenced by the restoration of citrate synthase (CS) activity, partial normalization of ATP level and NPPB mRNA expression in cAtg3-KO mice as well as upregulation of ADP level in WT mouse hearts. Besides, NNMT inhibition can rescue mitochondrial and cardiac dysfunction in cAtg3-KO mice by restoring NAD+ level. 4. The impact of autophagic flux upon cardiac and mitochondrial function Autophagy is an intracellular degradation pathway that recycles subcellular components, playing a critical in modulating metabolic homeostasis. Autophagic flux, a central homeostatic mechanism that degrades materials toxic to cardiomyocytes, can mediate SQSTM1-NF-κB-NNMT signal transduction to control the cellular level of NAD+, thereby maintaining the mitochondrial and cardiac function. 5. Conclusion Autophagic flux may be a potential way to maintain the cellular level of NAD to regulate mitochondrial and cardiac fiunction. . Reference [1] Abdellatif M, Sedej S, Kroemer G. NAD+ Metabolism in Cardiac Health, Aging, and Disease. Circulation. 2021;144(22):1795-1817. doi:10.1161/CIRCULATIONAHA.121.056589 [2] Zhang Q, Li Z, Li Q, et al. Control of NAD+ homeostasis by autophagic flux modulates mitochondrial and cardiac function. EMBO J. Published online January 11, 2024. doi:10.1038/s44318-023-00009-w About BONTAC BONTAC has rich R&D experience and advanced technology in the biosynthesis of NAD and NMN. Bonzyme whole-enzymatic method is adopted, which is environmental-friendly, with no harmful solvent residues. The purity of products can reach up to 95%, which is benefited from the exclusive Bonpure seven-step purification technology. BONTAC has self-owned factories and has obtained a number of international certifications, where high quality and stable supply of products can be ensured. BONTAC has over 160 domestic and foreign patents, leading the industry of coenzyme and natural products. In the future, BONTAC will actively expand the international market, and work with global partners to promote the prosperous development of synthetic biology industry. In this era full of challenges and opportunities, BONTAC is confident to make greater contributions to the cause of human health. Disclaimer This article is based on the reference in the academic journal. The relevant information is provide for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your reliance on the information and material on this website.
1. Introduction Heart failure is a serious condition in the development of cardiovascular disease. In particular, diastolic heart failure, as one of the most common manifestations of heart failure in the elderly, has always been viewed as a classic aging-related terminal illness due to its high prevalence and lack of effective treatment. Nicotinamide mononucleotide (NMN) raises the hope for the treatment of this illness. NMN can restore the functions of heart and blood vessels, protect the heart from damage after a heart attack, prevent heart failure by promoting the health of the mitochondria, and restore cardiovascular, cognitive, and metabolic decline. This study is dedicated to deciphering another mechanism of action for NMN administration, namely improving lysosomal ferroptosis to prevent heart failure. 2. The key pathogenesis of diastolic heart failure The effect of NMN on improving cardiac function is mainly realized by elevating the level of myocardial nicotinamide adenine dinucleotide (NAD+), an important coenzyme in the tricarboxylic acid cycle. The mitochondrial dysfunction and decreased ability of NAD+ biosynthesis are the key pathogenesis of diastolic heart failure. 3. Restoration of lysosomal function and autophagic function by NMN administration Lysosomal function is impaired owing to decreased NAD+ biosynthesis in vivo. NMN administration improves lysosomal function and activates amino acid metabolism in the mice with cardiomyocyte-specific knockout of p32 (p32cKO), yet barely affects the lysosomal morphology. Additionally, NMN administration improves the degradation mechanism of autophagy, as evidenced by the restoration of autophagic function post NMN administration. 4. The detailed mechanism of action for NMN administration on heart failure NMN administration does not restore functional mitochondrial damage caused by the inhibition of mitochondrial translation. These findings suggest that NMN administration improves heart failure by improving lysosomal function without improving mitochondrial function. 5. The involvement of ferroptosis in heart-specific mitochondrial translation defect The suppression of ferroptosis ameliorates heart failure. The expression levels of ferroptosis-related factors (Chac1, GPX4, and Ho1) are also diminished by NMN, indicating that ferroptosis in the p32cKO heart is improved by NMN administration. 6. The improvement of mitochondrial dysfunction-induced ferroptosis by NMN administration The ferroptosis is induced in the p32 knockdown cells, as attested by the mitochondrial translation defect and the downregulation of intracellular NAD+ and NADH levels. The induction of ferroptosis in lysosome is closely related to the amount of NAD+ biosynthesis. When intracellular NAD+ level is lowered, the intracellular iron deposition and lipid peroxide are induced, which however are ameliorated by NMN administration. 7. Conclusion Mechanically, NMN administration can prevent heart failure by improving lysosomal ferroptosis, opening up new insight for the treatment of this illness. Reference Yagi, Mikako et al. “Improving lysosomal ferroptosis with NMN administration protects against heart failure.” Life science alliance vol. 6,12 e202302116. 4 Oct. 2023, doi:10.26508/lsa.202302116 BONTAC NMN product features and advantages * “Bonzyme” Whole-enzymatic method (environmental-friendly; no harmful solvent residues) * Exclusive “Bonpure” seven-step purification technology, with high purity (up to 99.9%) and stability * Industrial leading technology: 15 domestic and international NMN patents * Self-owned factories and a number of international certifications to ensure high quality and stable supply of products * One-stop customized service for product solution * NMN raw material supplier of famous David Sinclair team of Harvard University Disclaimer This article is based on the reference in the academic journal. The relevant information is provide for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC.
Bontac in Boao Health Food Science Conference & Expo(FHE) From 22 to 25 February 2023, the Boao Health Food Science Conference and Expo was successfully held at the permanent venue of the Boao Forum for Asia in Hainan, China. This international conference build an international platform for exchange and cooperation among government, academia, industry, and industry, academia and research, which aims to promote the development of the health food industry through the exchange of scientific information at home and abroad. Bontac performace in FHE The conference gathered several prominent scientists including 10 academicians, over 200 experts and scholars, and invited many popular food enterprises likely Nestle, Pepsi from the United States, Europe, Japan, Australia, New Zealand and other countries. More importantly, exhibition featured a number of high-tech companies that focus on high-tech development of the production of nutritious and healthy food products. As one of the high-tech companies attending the exhibition, Bontac, which has obtained over 160 international patents and is committed to the design of new biosynthetic pathways to explore and mass-produce natural products for food ingredients, was invited to attend the conference and companies vital stake holders to deliver academic views on the technological innovation and healthy development of the food industry. Figure 1: Xinhua Officical Record for Bontac in FHE Bontac Products in FHE Expo Bontac main products starring NMN, rare ginsenosides, NAD, NADH and NADPH were all present at booth C34 in FHE Expo. And that booth C34 attracted lots of exhibitors to consult who communicated with each other upon appearance owing to the obvious striking advantages likely Bontac manufacture technology of whole coenzyme, sustainable supply chain, complete quality system and environment-protection and energy-saving preparation. What’s more, the academician of the Chinese Academy of Engineering and Chairman of FHE, Chen Junshi also visited Bontac booth and highly commend on the Bontac performance and demonstration. Figure 2: Chen Visited Bontac Booth in FHE Bontac recognizes the importance of the upstream of raw material side in biotechnology as the key to product innovation. On the other hand, with the increasingly demand for high-quality food, synthetic biotechnology stands on the point of the potential to provide consumers with greener and healthier food ingredients. Therefore, as far as Bontac is concerned, developing and shaping innovative technology ownership supports to effectively solving the problem of insufficient plant and animal extracts, reducing the environmental burden, and contributing to carbon neutrality and human sustainable development. At present, Bontac has already launched industrialized stevioside and rare ginsenoside which can be utilized in the field of health food. In future, Bontac will set up more product lines for more raw materials with higher purity and better quality as health food ingredients. Bontac honor time in FHE It was great honor for Bontac to win innovative product enterprise award, which identified Bontac long-term commitment to the exploration and innovation of synthetic biology and health technology products. Furthermore, it also reflects the R&D capability and innovation ability of Bontac in the field of synthetic biology, which will surely inspire Bontac to invest more actively in R&D and innovation. Figure 3: Bontac Award in FHE Dr. Qi Zhang, Founder and Chief Scientist of Bontac, delivered a speech entitled Efficient Green Biosynthesis of Ginsenosides, NMN and other Natural Products at the Innovative Technology and Innovative Manufacturing forum, explaining the green safety, wide applicability and innovative value of synthetic biotechnology from the theoretical source. Figure 4: Dr. Zhang in FHE Dr. Zhang demonstrated that Bontac holds up on the technology of biosynthesis of coenzyme preparation for natural products such as ginsenosides, especially rare ginsenosides Rh2 and Rg3. The advantages focuses on breaking through the limitations of raw materials, facilitating industrial scale-up, shorting reaction cycle, milder conditions, green environment and energy saving, but maintains the point of sustainable development. On the 23rd, a roundtable discussion on the "Technology and Investment in the Food Industry". Shu Shangke, Chairman of Bontac, attended the forum on the theme of Technology and Investment in the Food Industry and said that synthetic biotechnology is bringing about a revolution in the food and pharmaceutical fields, pushing these fields to iterate and upgrade. In the food industry, having strong R&D strength, leading technology and abundant patents are important factors for a company to have core competitiveness and investment value. Figure 5: Shu in FHE